Cagent Vascular Announces Initial RECOIL Study Results: Serranator Demonstrates 49% Less Recoil Than POBA In BTK Arteries

Cagent Vascular, the exclusive developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its Below-the-Knee (BTK) RECOIL study.

This Core Lab-Adjudicated Recoil analysis, the first of its kind, evaluated vessel recoil in lesions treated with Serranator® verses Plain Old Balloon Angioplasty (POBA). The study results demonstrated that lesions treated using Serration Angioplasty exhibited 49% less average recoil than POBA. Dr. Stefan Stahlhoff, MD (Arnsberg Clinic, Arnsberg, Germany) and Dr. Venita Chandra (Stanford University, Stanford, CA USA) led the RECOIL study as co-principal investigators.

The Serranator PTA Serration Balloon Catheter (Serranator) is the first and only angioplasty balloon FDA Cleared and CE Marked that embeds serration technology into a semi-compliant balloon for treating Peripheral Artery Disease (PAD). The device is designed to create multiple longitudinal lines of interrupted micro-serrations to aid arterial expansion.

Read the full article here

Previous

Next